RAP 0.00% 20.5¢ resapp health limited

Ann: Clinical study to develop COVID-19 screening test, page-20

  1. 26,627 Posts.
    lightbulb Created with Sketch. 1728
    Too late for what? We invested in ResAppDx, this is the product that has massive revenue potential....DYOR.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.